[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100613486":3},{"organization":4,"outcomesModule":7,"designInfo":28,"detailedDescription":34,"studyPopulation":27,"armGroups":35,"interventions":45,"overallOfficials":27,"centralContacts":53,"locations":59,"responsibleParty":77,"collaborators":27,"id":79,"slug":27,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":27,"eligibilityCriteria":84,"healthyVolunteers":85,"sex":86,"minAge":87,"maxAge":27,"enrollmentInfo":88,"targetDuration":27,"studyType":91,"phases":92,"briefSummary":94,"conditions":95,"keywords":27,"overallStatus":62,"whyStopped":27,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Daewoong Pharmaceutical Co. LTD.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":17,"otherOutcomes":27},[9,13],{"measure":10,"description":11,"timeFrame":12},"Cmax","Cmax of DWJ1622 and DWC202313, DWC202314","At pre-dose (0 hours), and post-dose 1 to 72 hours.",{"measure":14,"description":15,"timeFrame":16},"AUClast","AUClast of DWJ1622 and DWC202313, DWC202314","Time Frame: At pre-dose (0 hours), and post-dose 1 to 72 hours.",[18,21,24],{"measure":19,"description":20,"timeFrame":12},"AUCinf","AUCinf of DWJ1622 and DWC202313, DWC202314",{"measure":22,"description":23,"timeFrame":12},"AUClast\u002FAUCinf","AUClast\u002FAUCinf of DWJ1622 and DWC202313, DWC202314",{"measure":25,"description":26,"timeFrame":12},"Tmax","Tmax of DWJ1622 and DWC202313, DWC202314",null,{"allocation":29,"interventionModel":30,"interventionModelDescription":27,"primaryPurpose":31,"observationalModel":27,"timePerspective":27,"maskingInfo":32},"RANDOMIZED","CROSSOVER","TREATMENT",{"masking":33,"maskingDescription":27,"whoMasked":27},"NONE","This is an open-label, randomized, oral, single-dose, 2-sequence, 2-period, crossover Phase 1 study to evaluate the pharmacokinetics and safety profiles of DWJ1622, DWC202313, and DWC202314 in healthy volunteers under fed conditions. Subjects will be randomized to receive either DWJ1622 or the co-administration of DWC202313 and DWC202314 in different sequences across two study periods with an appropriate washout period.\n\nThe primary pharmacokinetic endpoints include the maximum observed plasma concentration (Cmax) and the area under the plasma concentration-time curve to the last measurable concentration (AUClast) of each study drug. Secondary endpoints include the area under the plasma concentration-time curve extrapolated to infinity (AUCinf), the ratio of AUClast to AUCinf (AUClast\u002FAUCinf), the time to reach maximum plasma concentration (Tmax), and the terminal elimination half-life (t1\u002F2). Safety will be evaluated based on adverse events and clinical laboratory tests.",[36,42],{"label":37,"type":38,"description":27,"interventionNames":39},"DWJ1622","EXPERIMENTAL",[40,41],"Drug: DWJ1622","Drug: DWC202313, DWC202314",{"label":43,"type":38,"description":27,"interventionNames":44},"DWC202313, DWC202314",[40,41],[46,50],{"type":47,"name":37,"description":48,"armGroupLabels":49,"otherNames":27},"DRUG","DWJ1622 (single oral dose) is administered in accordance with the study protocol.",[43,37],{"type":47,"name":43,"description":51,"armGroupLabels":52,"otherNames":27},"DWC202313, DWC202314(single oral dose) is administered in accordance with the study protocol.",[43,37],[54],{"name":55,"role":56,"phone":57,"phoneExt":27,"email":58},"SHIN","CONTACT","825508858","hbshin028@daewoong.co.kr",[60],{"facility":61,"status":62,"city":63,"state":64,"zip":65,"country":66,"countryCode":27,"cosmosGeoPoint":67,"geoPoint":72,"contacts":73},"H Plus YANGJI Hospital","RECRUITING","Seoul","Gwanak-gu","08779","South Korea",{"type":68,"coordinates":69},"Point",[70,71],126.9784,37.566,{"lat":71,"lon":70},[74],{"name":75,"role":56,"phone":76,"phoneExt":27,"email":27},"Bae","8218778875",{"type":78,"investigatorFullName":27,"investigatorTitle":27,"investigatorAffiliation":27,"oldNameTitle":27,"oldOrganization":27},"SPONSOR","100613486",false,"NCT07267221","Bioequivalence Study for the Safety and the Pharmacokinetics of DWC202313, DWC202314, and DWJ1622 in Healthy Volunteers Under Fed Condition.","An Open-label, Randomized, Fed, Single-dose, 2-sequence, 2-period, Crossover Phase 1 Study to Evaluate the Pharmacokinetics and the Safety After Administration of \"DWJ1622\" and Co-administration of \"DWC202313\" and \"DWC202314\" in Healthy Volunteers","Inclusion Criteria:\n\n* Over 19 year old\n* Healthy adult volunteers\n\nExclusion Criteria:\n\n* with a history of mental disorder\n* For female volunteers, those who are suspected of being pregnant or lactating",true,"ALL","19 Years",{"count":89,"type":90},36,"ESTIMATED","INTERVENTIONAL",[93],"PHASE1","This study aims to evaluate the safety and pharmacokinetic characteristics of DWJ1622, DWC202313, and DWC202314 in healthy adult volunteers under fed conditions.",[96],"Healthy Volunteers","2025-12-03",{"date":99,"type":100},"2025-12-05","ACTUAL",{"date":102,"type":90},"2025-12-01",{"date":104,"type":90},"2026-05-30",{"name":5,"class":6},1]